American Society of Hematology

Figure 1.

Patient treatment assignments and outcomes. RTX indicate rituximab 375 mg/m2 weekly × 3 doses and cycle length, 21 days; LMP, 2 × 107 cells per m2 weekly × 2 and cycle length, 42 days. Alive, alive with further therapy and/or relapse; CCR, continous complete remission; DOAC, dead of other causes; DOD, dead of disease.

Patient treatment assignments and outcomes. RTX indicate rituximab 375 mg/m² weekly × 3 doses and cycle length, 21 days; LMP, 2 × 10⁷ cells per m² weekly × 2 and cycle length, 42 days. Alive, alive with further therapy and/or relapse; CCR, continous complete remission; DOAC, dead of other causes; DOD, dead of disease.

This Feature Is Available To Subscribers Only